Home > About us > Why we do this

Why we do this

 

Most of the world's malaria deaths occur in Africa and in vulnerable populations, yet most malaria research is led by academics from Europe and North America, and most early drug development studies are conducted in non-African populations. Our group aims to lead research that can improve the treatment of malaria in Africa, and globally. Together with vector control, better treatments will contribute to the control and eventual elimination of malaria. Drug (and insecticide) resistance are the main obstacles to malaria control to elimination, which South Africa aims optimistically to achieve by 2018. Over the past 2-5 years, we have extended our partnerships and collaborations and this has culminated in the formation of CCOAT, linking drug discovery by UCT's H3-D initiative, with clinical drug development (sponsored by the South African government's Technology Innovation Agency and the Medicines for Malaria Venture) and informing national and global malaria treatment guidelines.

 

Information about one of our collaborators: Medicines for Malaria Venture (MMV)